AZD5423 Multiple Ascending Dose study

Study identifier:D2340C00002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled AZD5423 after Administration of Multiple Ascending Doses for 14 days in Healthy Male and Female Subjects

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD5423, Placebo

Sex

All

Actual Enrollment

27

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Jan 2010
Primary Completion Date: 01 Apr 2010
Study Completion Date: 01 Apr 2010

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria